TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04180969
Drug: yohimbine + hydrocortisone
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine 54mg + hydrocortisone 20mg oral
Study: NCT04180969
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo stressor
Study: NCT04742010
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes
Study: NCT04742010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: as above
Study: NCT04981704
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin Capsules
Study: NCT05387603
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
Study: NCT05775874
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation dose: 80mg BID,po.
Study: NCT06412861
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Study: NCT05163041
Drug: BT7480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
Study: NCT05934526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule containing placebo
Study: NCT05999240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
Study: NCT01675986
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g
Study: NCT05000346
Drug: Drug, inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution administered by inhalation
Study: NCT06133101
Drug: Standard Soy Milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of commercially available soy milk
Study: NCT06133101
Drug: 2% Fat Cow's Milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of commercially available 2% cow's milk
Study: NCT06759363
Drug: Calcium Butyrate
Normalized name: calcium butyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day of calcium-butyrate
Study: NCT04456439
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
Study: NCT05048875
Drug: JNJ-64281802 (sentinel high dose)
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1a, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
Study: NCT05048875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic effect, used as a control in testing new drugs
Study: NCT04754100
Drug: agenT-797
Normalized name: MISCELLANEOUS AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study: NCT05086445
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05086445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05235854
Drug: Injection of corticosteroids (Diprostène®)
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
Study: NCT04593160
Drug: Diclofenac potassium- acetaminophen combination
Normalized name: acetaminophen / diclofenac potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
Study: NCT04593160
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative single dose of diclofenac potassium(50mg)
Study: NCT04593160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative single dose of placebo
Study: NCT05780463
Drug: MP0420
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
Study: NCT05780463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution
Study: NCT06622239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 6 weeks
Study: NCT06441994
Drug: PSW-1025
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
Study: NCT05881915
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
Study: NCT05914805
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
Study: NCT06590961
Drug: UBX-303061
Approvals — FDA: no, EMA: no, PMDA: no
Description: UBX-303061 oral dosage
Study: NCT00002136
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05544916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/day, for 5 days
Study: NCT05616728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT06377410
Drug: Syrup Prospan
Normalized name: Irospan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant with stable COPD who received Syrup prospan for 1 month
Study: NCT06212492
Drug: NMBAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and systematic use of NMBAs
Study: NCT05132920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
Study: NCT06605118
Drug: Azithromycin Injection
Normalized name: azithromycin Injection
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg azithromycin in 250 mL of normal saline
Study: NCT06605118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of normal saline
Study: NCT06605118
Drug: Standard of Care Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision
Study: NCT06654336
Drug: ELIGARD 22.5mg
Normalized name: Eligard 22.5mg Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
Study: NCT06370975
Drug: 3% hypertonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Study: NCT06370975
Drug: Ringer's lactated solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Study: NCT06370975
Drug: 0.9% Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Study: NCT06655870
Drug: mRNA-0184
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05006911
Drug: Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
Study: NCT05533411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT05032807
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol 1000mg standard formulation, single dose, oral
Study: NCT05032807
Drug: Novel formulation
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol 1000mg with lipid matrix, single dose, oral
Study: NCT04989101
Drug: Nigella
Normalized name: NIGELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
Study: NCT05792878
Drug: nucleoside analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: The naive treated patients with chronic hepatitis B were given antiviral treatment with nucleoside analogues according to their condition.
Study: NCT04970797
Drug: Xinglouchengqi decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
Study: NCT05755997
Drug: 0.9 % NaCl
Normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% NaCl per day for 4 days every month for 1 year
Study: NCT05191680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match apalutamide
Study: NCT05051007
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
Study: NCT06670053
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician.
Study: NCT06405243
Drug: Myoinositol
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
Study: NCT04511039
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05634759
Drug: Azithromycin for Routine Community-wide MDA
Normalized name: azithromycin Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.
Study: NCT05634759
Drug: Two Additional Rounds of Azithromycin for Children
Normalized name: azithromycin Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
Study: NCT05634759
Drug: Azithromycin for Second Community-wide MDA
Normalized name: azithromycin Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
Study: NCT04958538
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
Study: NCT04176978
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient in this group will receive Rosuvastatin 20mg daily.
Study: NCT06558032
Drug: Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the test drug was given orally under fasting condition
Study: NCT05947409
Drug: SMARTO ONE
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
Study: NCT05398198
Drug: GSK3923868
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3923868 dose and administration as per study intervention.
Study: NCT05398198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK3923868 will be administered.
Study: NCT05726136
Drug: albumin 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Study: NCT05321979
Drug: MBA-P01
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBA-P01 will be injected into the Glabellar line.
Study: NCT06049498
Drug: Mongolian Medicine ZhenBao Pills Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
Study: NCT05311618
Drug: NGM438
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study: NCT05199129
Drug: HCP1904-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 8 weeks orally
Study: NCT05199129
Drug: RLD2001-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take once daily for 8 weeks orally
Study: NCT04856371
Drug: CYH33
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
Study: NCT04866225
Drug: Oral [14C]PF-06865571
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral radiolabeled PF-06865571
Study: NCT04866225
Drug: IV [14C]PF-06865571
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV radiolabeled PF-06865571
Study: NCT05851066
Drug: VSA003
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
Study: NCT05851066
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05499312
Drug: HKIIM-KU formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
Study: NCT05499312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
Study: NCT06259747
Drug: Doxylamine and Pyridoxine
Normalized name: Doxylamine and pyridoxine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional medical treatment for nausea and vomiting during pregnancy
Study: NCT05479058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT05485064
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
Study: NCT05485064
Drug: placebo needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
Study: NCT06462027
Drug: Packed Red Blood Cells (1 unit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
Study: NCT06462027
Drug: Packed Red Blood Cells (2 units)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
Study: NCT06500247
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Study: NCT04880616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules matching NBI-827104 for oral administration
Study: NCT04870333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.
Study: NCT04870333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
Study: NCT05591105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of surgery, they will continue receiving analgesia according the schedule.
Study: NCT06373991
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection of cyclophosphamide.
Study: NCT06304220
Drug: Cerazet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparation of the utilization of two distinct progestogens for pituitary suppression
Study: NCT06320067
Drug: Androgen Deprivation Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
Study: NCT06320067
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone should also be administered 5mg daily using local pharmacy prescribing.
Study: NCT06056752
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
Study: NCT04965688
Drug: Drug determined by treating oncologist based on recommendation from systems biology analysis.
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
Study: NCT04431518
Drug: JULUCA 50Mg-25Mg Tablet
Normalized name: JULUCA 50mg-25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of JULUCA will be taken daily for up to 14 days
Study: NCT05866055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.